Lv5
860 积分 2024-10-16 加入
Leading RNA Interference Therapeutics Part 2: Silencing Delta-Aminolevulinic Acid Synthase 1, with a Focus on Givosiran
1天前
待确认
Applied Survival Analysis
13天前
已完结
Inhibition of C3 with APL-2 Results in Normalisation of Markers of Intravascular and Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
16天前
已关闭
Plasma-Pooling Methods To Increase Throughput for in Vivo Pharmacokinetic Screening
27天前
已完结
A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration
28天前
已完结
An industry perspective on hyaluronidase co-formulated biopharmaceutics
1个月前
已完结
A comparison of the four most commonly used formulae to adjust the QT-interval for heart rate in 22,000 healthy subjects
1个月前
已完结
Correction to: Scientific white paper on concentration-QTc modeling
1个月前
已完结
Scientific white paper on concentration-QTc modeling
1个月前
已完结
Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia
2个月前
已完结
皖公网安备34019202002308
